Posted by Michael Wonder on 19 Jul 2016
EMA publishes EPAR for Zinbryta (daclizumab)
19 July 2016 - The EMA has published an EPAR for Biogen's Zinbryta.
The European Commission approved daclizumab on 1 July 2016 for use in adult patients for the treatment of relapsing forms of multiple sclerosis.
